HLT:PA:PA-Lyxor Index Fund - Lyxor STOXX Europe 600 Healthcare UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 142.815

Change

0.00 (0.00)%

Market Cap

USD 0.77B

Volume

4.35K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.41 (-0.89%)

USD 61.38B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+3.90 (+0.68%)

USD 13.43B
WRD:PA HSBC MSCI World UCITS ETF

+0.25 (+0.70%)

USD 11.05B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+2.50 (+0.61%)

USD 9.62B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+5.50 (+1.09%)

USD 8.88B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+2.53 (+1.06%)

USD 8.55B
HHH:PA HSBC S&P 500 UCITS ETF

+0.40 (+0.68%)

USD 7.68B
WLD:PA Lyxor UCITS MSCI World D-EUR

+2.31 (+0.64%)

USD 7.63B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.12 (+0.65%)

USD 6.83B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

+1.29 (+0.78%)

USD 5.48B

ETFs Containing HLT:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.06% 32% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.06% 32% F 38% F
Trailing 12 Months  
Capital Gain 2.11% 18% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.11% 15% F 43% F
Trailing 5 Years  
Capital Gain 31.23% 52% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.23% 47% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 8.80% 55% F 60% D-
Dividend Return 8.80% 51% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.33% 73% C 87% B+
Risk Adjusted Return 105.64% 88% B+ 93% A
Market Capitalization 0.77B 75% C 76% C+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike